{"results":[{"id":"226747283846","name":"Large language model (LLM)-as-a-judge for clinical variable extraction review","url":"https://resources.flatiron.com/publications/large-language-model-llm-as-a-judge-for-clinical-variable-extraction-review","featuredImage":null,"featuredImageAltText":null,"postSummary":"Overview While large language models (LLMs) enable scalable extraction of clinical variables from unstructured electronic health records, sparse documentation or complex clinical text can result in extraction errors.…","publishDate":"2026-11-11T22:05:01Z","language":"en","journal":"ESMO AI & Digital Oncology","authors":"Walsh C, Viani N, Schwarz A, et al.","externalUrl":null,"tags":[{"name":"Publication summary","url":"https://resources.flatiron.com/publications/tag/publication-summary"},{"name":"Publications","url":"https://resources.flatiron.com/publications/tag/publications"},{"name":"Machine learning","url":"https://resources.flatiron.com/publications/tag/machine-learning"},{"name":"Prostate Cancer","url":"https://resources.flatiron.com/publications/tag/prostate-cancer"},{"name":"Artificial intelligence","url":"https://resources.flatiron.com/publications/tag/artificial-intelligence"},{"name":"Germany Publications","url":"https://resources.flatiron.com/publications/tag/germany-publications"},{"name":"UK Publications","url":"https://resources.flatiron.com/publications/tag/uk-publications"}]},{"id":"226747658320","name":"Development and evaluation of LLM-based extraction workflows to accelerate prostate cancer evidence generation in Germany","url":"https://resources.flatiron.com/publications/development-and-evaluation-of-llm-based-extraction-workflows-to-accelerate-prostate-cancer-evidence-generation-in-germany","featuredImage":null,"featuredImageAltText":null,"postSummary":"Overview Extracting clinical information from unstructured electronic health records (EHRs) at scale is essential for generating real-world evidence, but data reliability requires rigorous evaluation. In this study,…","publishDate":"2026-11-11T22:05:00Z","language":"en","journal":"ESMO AI & Digital Oncology","authors":"Viani N, Schwarz A, Hashemian A, et al.","externalUrl":null,"tags":[{"name":"Publication summary","url":"https://resources.flatiron.com/publications/tag/publication-summary"},{"name":"Publications","url":"https://resources.flatiron.com/publications/tag/publications"},{"name":"Machine learning","url":"https://resources.flatiron.com/publications/tag/machine-learning"},{"name":"Prostate Cancer","url":"https://resources.flatiron.com/publications/tag/prostate-cancer"},{"name":"Artificial intelligence","url":"https://resources.flatiron.com/publications/tag/artificial-intelligence"},{"name":"Germany Publications","url":"https://resources.flatiron.com/publications/tag/germany-publications"}]},{"id":"226054816119","name":"Treatment patterns and outcomes post-CAR T failure in LBCL: the \"what comes next\" question","url":"https://resources.flatiron.com/publications/treatment-patterns-and-outcomes-post-car-t-failure-in-lbcl-the-what-comes-next-question","featuredImage":null,"featuredImageAltText":null,"postSummary":"Overview While chimeric antigen receptor T-cell (CAR T) therapy has advanced care for relapsed or refractory large B-cell lymphoma (LBCL), over half of patients eventually experience disease relapse. This real-world…","publishDate":"2026-11-04T14:00:06Z","language":"en","journal":"ASH Annual Meeting","authors":"Fullerton C, Bye M, Kaur M, Sawas A.","externalUrl":null,"tags":[{"name":"Publication summary","url":"https://resources.flatiron.com/publications/tag/publication-summary"},{"name":"Publications","url":"https://resources.flatiron.com/publications/tag/publications"},{"name":"Hematologic malignancies","url":"https://resources.flatiron.com/publications/tag/hematologic-malignancies"},{"name":"HEOR / RWE","url":"https://resources.flatiron.com/publications/tag/heor-rwe"},{"name":"Treatment and Testing patterns","url":"https://resources.flatiron.com/publications/tag/treatment-and-testing-patterns"}]},{"id":"226080919591","name":"Real-world comparison of biologic features, treatment patterns, and clinical outcomes between younger (≤55 years) and older (>55 years) patients with CLL receiving frontline targeted therapy","url":"https://resources.flatiron.com/publications/real-world-comparison-of-biologic-features-treatment-patterns-and-clinical-outcomes-between-younger-55-years-and-older-55-years-patients-with-cll-re-1793396111881","featuredImage":null,"featuredImageAltText":null,"postSummary":"Overview Patients aged ≤55 years represent a small minority of individuals with chronic lymphocytic leukemia (CLL). This study compared biological features, frontline treatment patterns, and real-world outcomes between…","publishDate":"2026-11-04T14:00:05Z","language":"en","journal":"ASH Annual Meeting","authors":"Ermann DA, Willis H, Wang X, et al.","externalUrl":null,"tags":[{"name":"Publication summary","url":"https://resources.flatiron.com/publications/tag/publication-summary"},{"name":"Publications","url":"https://resources.flatiron.com/publications/tag/publications"},{"name":"Hematologic malignancies","url":"https://resources.flatiron.com/publications/tag/hematologic-malignancies"},{"name":"HEOR / RWE","url":"https://resources.flatiron.com/publications/tag/heor-rwe"},{"name":"Treatment and Testing patterns","url":"https://resources.flatiron.com/publications/tag/treatment-and-testing-patterns"}]},{"id":"226054891853","name":"When MRD matters: clinical interpretation and treatment decision-making after measurable residual disease testing in multiple myeloma","url":"https://resources.flatiron.com/publications/when-mrd-matters-clinical-interpretation-and-treatment-decision-making-after-measurable-residual-disease-testing-in-multiple-myeloma","featuredImage":null,"featuredImageAltText":null,"postSummary":"Overview Measurable residual disease (MRD) testing detects small amounts of cancer remaining after treatment and is increasingly used to assess treatment response in multiple myeloma, a cancer of plasma cells. However,…","publishDate":"2026-11-04T14:00:05Z","language":"en","journal":"ASH Annual Meeting","authors":"Sawas A, Glickman S, Buhl C, Pfeffer D, Rios G.","externalUrl":null,"tags":[{"name":"Publication summary","url":"https://resources.flatiron.com/publications/tag/publication-summary"},{"name":"Publications","url":"https://resources.flatiron.com/publications/tag/publications"},{"name":"Machine learning","url":"https://resources.flatiron.com/publications/tag/machine-learning"},{"name":"Artificial intelligence","url":"https://resources.flatiron.com/publications/tag/artificial-intelligence"},{"name":"Hematologic malignancies","url":"https://resources.flatiron.com/publications/tag/hematologic-malignancies"},{"name":"Treatment and Testing patterns","url":"https://resources.flatiron.com/publications/tag/treatment-and-testing-patterns"}]},{"id":"226054900018","name":"Association of lymphopenia with outcomes in diffuse large B cell lymphoma in the era of T-cell directed therapies","url":"https://resources.flatiron.com/publications/association-of-lymphopenia-with-outcomes-in-diffuse-large-b-cell-lymphoma-in-the-era-of-t-cell-directed-therapies","featuredImage":null,"featuredImageAltText":null,"postSummary":"Overview Absolute lymphocyte count (ALC) is a marker of immune status, but its prognostic role in diffuse large B-cell lymphoma (DLBCL) in the era of T-cell-directed therapies remains understudied. This retrospective…","publishDate":"2026-11-04T14:00:03Z","language":"en","journal":"ASH Annual Meeting","authors":"Kowshik N, Boston J, Chica D, et al.","externalUrl":null,"tags":[{"name":"Publication summary","url":"https://resources.flatiron.com/publications/tag/publication-summary"},{"name":"Publications","url":"https://resources.flatiron.com/publications/tag/publications"},{"name":"Hematologic malignancies","url":"https://resources.flatiron.com/publications/tag/hematologic-malignancies"},{"name":"HEOR / RWE","url":"https://resources.flatiron.com/publications/tag/heor-rwe"}]},{"id":"226054891409","name":"Frontline treatment and consolidation strategies and associated outcomes in primary central nervous system lymphoma: a large US real-world study","url":"https://resources.flatiron.com/publications/frontline-treatment-and-consolidation-strategies-and-associated-outcomes-in-primary-central-nervous-system-lymphoma-a-large-us-real-world-study","featuredImage":null,"featuredImageAltText":null,"postSummary":"Overview Primary central nervous system lymphoma (PCNSL) is a rare and aggressive subtype of extranodal B-cell lymphoma with no standardized care pathway. This study characterized clinical characteristics, treatment…","publishDate":"2026-11-04T14:00:03Z","language":"en","journal":"ASH Annual Meeting","authors":"Proli A, Khan F, Qian Y, Buhl C, Sawas A.","externalUrl":null,"tags":[{"name":"Publication summary","url":"https://resources.flatiron.com/publications/tag/publication-summary"},{"name":"Publications","url":"https://resources.flatiron.com/publications/tag/publications"},{"name":"Hematologic malignancies","url":"https://resources.flatiron.com/publications/tag/hematologic-malignancies"},{"name":"HEOR / RWE","url":"https://resources.flatiron.com/publications/tag/heor-rwe"},{"name":"Treatment and Testing patterns","url":"https://resources.flatiron.com/publications/tag/treatment-and-testing-patterns"}]},{"id":"226080918623","name":"Treatment patterns across lines of therapy among patients with newly diagnosed multiple myeloma in the United States","url":"https://resources.flatiron.com/publications/treatment-patterns-across-lines-of-therapy-among-patients-with-newly-diagnosed-multiple-myeloma-in-the-united-states","featuredImage":null,"featuredImageAltText":null,"postSummary":"Overview The treatment landscape for newly diagnosed multiple myeloma (NDMM) has evolved rapidly with the introduction of anti-CD38 monoclonal antibodies (aCD38), but contemporary treatment patterns remain poorly…","publishDate":"2026-11-04T14:00:02Z","language":"en","journal":"ASH Annual Meeting","authors":"Grajales-Cruz AF, Cole C, Biran N, et al.","externalUrl":null,"tags":[{"name":"Publication summary","url":"https://resources.flatiron.com/publications/tag/publication-summary"},{"name":"Publications","url":"https://resources.flatiron.com/publications/tag/publications"},{"name":"Hematologic malignancies","url":"https://resources.flatiron.com/publications/tag/hematologic-malignancies"},{"name":"Treatment and Testing patterns","url":"https://resources.flatiron.com/publications/tag/treatment-and-testing-patterns"}]},{"id":"226080918536","name":"Real-world treatment patterns of novel immune-based therapy utilization in relapsed/refractory multiple myeloma: evidence from a contemporary cross-sectional analysis","url":"https://resources.flatiron.com/publications/real-world-treatment-patterns-of-novel-immune-based-therapy-utilization-in-relapsed/refractory-multiple-myeloma-evidence-from-a-contemporary-cross-s-1793397874220","featuredImage":null,"featuredImageAltText":null,"postSummary":"Overview Recent guideline updates supporting the use of BCMA- and GPRC5D-directed (novel) therapies in earlier lines of therapy have expanded treatment options for patients with relapsed/refractory multiple myeloma…","publishDate":"2026-11-04T14:00:02Z","language":"en","journal":"ASH Annual Meeting","authors":"Biran N, Edwin N, Grajales-Cruz A, et al.","externalUrl":null,"tags":[{"name":"Publication summary","url":"https://resources.flatiron.com/publications/tag/publication-summary"},{"name":"Publications","url":"https://resources.flatiron.com/publications/tag/publications"},{"name":"Hematologic malignancies","url":"https://resources.flatiron.com/publications/tag/hematologic-malignancies"},{"name":"Treatment and Testing patterns","url":"https://resources.flatiron.com/publications/tag/treatment-and-testing-patterns"}]}],"paging":{"next":{"after":"OQ=="}},"total":545}